Therapeutic Advances in Psychopharmacology
December 4, 2025
Charles Dodds, Rachelle Dawson, Alexander Lim et al.
3 citations
Novel interventions for post-traumatic stress disorder (PTSD) leverage the psychoactive properties of psychedelic compounds, such as ketamine, 3,4-methylenedioxymethamphetamine and psilocybin, which may overcome limitations of conventional treatments. Through the modulation of pathways involved in synaptic plasticity, psychedelic interventions are believed to enhance the mechanisms underlying...
Molecular Psychiatry
December 1, 2025
Yuanpeng Li, Hongyuan Li, Hongshuang Wang et al.
Psychedelics, particularly psilocybin, have garnered significant attention as potential therapeutic tools for treating substance use disorders (SUDs), such as those related to alcohol, nicotine, heroin (an opioid), or cocaine. Traditional treatments often fall short, leading to high relapse rates and an urgent need for innovative approaches. This article explores the emerging role of...
Emerging Trends in Drugs, Addictions, and Health
December 1, 2025
Federico Seragnoli
Introduction Psychedelic Assisted Psychotherapy (PAP) has been legal in Switzerland since 2014 under supervised exceptional medical use with MDMA, LSD and Psilocybin with case by case authorisations delivered from the Federal Office of Public Health. In particular, since 2021, we have implemented a clinical activity at Geneva University Hospital (HUG) for treatment resistant patients using LSD...
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice
December 1, 2025
Johannes Klaus, Fritz Schneider, Rena Schaletzky et al.
Abstract: Background: Psychedelic-assisted therapy is increasingly being explored as potential treatment for substance use disorders (SUDs). While multiple systematic reviews and meta-analyses have examined this topic, the efficacy, methodological quality, and overlap of the existing evidence base remain unclear. Methods: We conducted an umbrella review of systematic reviews and meta-analyses...
Philosophical Psychology
November 30, 2025
Julian Kiverstein, Hüseyin Beyköylü, Michiel van Elk
3 citations
Psychedelic research has shown that the effects of serotonergic substances, such as psilocybin and LSD, are strongly influenced by the interaction of substance, set, and setting. Mystical-type experiences, often induced by psychedelics, are not solely driven by pharmacological mechanisms but emerge from a dynamic interplay between the psychological state (set), external environment (setting),...
CNS Drugs
November 28, 2025
D J Hirsch, Jace Reed, Aasim Naqvi et al.
2 citations
Eating disorders (EDs) are complex psychiatric conditions characterized by disruptions in eating behaviors, body image concerns, and profound medical and psychosocial consequences. Despite their significant global prevalence, coupled with high morbidity and mortality rates, pharmacological treatment options remain limited. This review synthesizes evidence from clinical drug trials conducted...
Discover Mental Health
November 27, 2025
Sean M. Viña
The renewed interest in psychedelics for mental health treatment presents both promise and complexity. Substances like psilocybin and MDMA have shown potential in addressing conditions such as PTSD and depression, particularly when administered in supportive contexts. Yet as these therapies move toward mainstream adoption, concerns arise about rapid medicalization, corporate monopolization, and...
bioRxiv
November 26, 2025
Rui Dai, Rodrigo Cofré, Christopher Timmermann et al.
preprint
The mechanism of psychedelic drug action is a dynamic area of neuroscience, with two major lines of investigation: (1) laboratory studies at the molecular and cellular level, and (2) human neuroimaging studies of functional brain networks. Despite considerable progress, there remains insufficient understanding of the link between molecular/cellular substrates of psychedelics and the whole-brain...
Journal of Psychiatric Research
November 26, 2025
Michael van Ameringen, Vidhi Patel, Beth Patterson et al.
The etiology of OCD is complex and appears to involve multiple biological pathways. Imbalances in central serotonin, dopamine, and glutamate activities are widely thought to play a causative role. Despite strong evidence supporting first-line OCD pharmacotherapies, approximately 40-60 % of OCD patients remain unresponsive and are considered treatment resistant (TR). Although a range of agents...
Harm Reduction Journal
November 25, 2025
Daniel J. Kruger, Gina Mersereau, Ashley Sullivan et al.
1 citation
BACKGROUND: The use of psychedelics is currently increasing in the United States. Awareness of clinical trials investigating the therapeutic applications of psychedelics may result in a record number of people who use psychedelics for the first-time. This study aimed to develop a harm-reduction resource to facilitate safe and successful psychedelic experiences outside of regulated clinical and...